{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:39:09Z","timestamp":1792683549762,"version":"4.5.0"},"reference-count":0,"publisher":"The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS","issue":"4","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Turkish Journal of Medical Sciences"],"abstract":"<jats:p>Background\/aim\u02d0 This study aims to investigate the prevalence of malignancy in patients with inflammatory bowel disease (IBD) followed up in a tertiary reference center.\nMaterials and methods\u02d0 IBD patients with at least 6 months of follow-up from the gastroenterology clinic between 2000 and 2022 wereevaluated retrospectively in a tertiary center. Patient information was obtained from the patient registration system.\nResults\u02d0 There were 697 patients in the study, 320 (45.9%) of these were female. The mean age of the patients at IBD diagnosis was 33.4\u00b1 13.1 years. The mean follow-up time was 93.1 \u00b1 64.8 (median 84, IQR (25\u201375) (36\u2013144)) months. IBD types were as; 315 (45.2%) hadulcerative colitis, and 382 (54.8%) had Crohn\u2019s disease. Before the diagnosis of IBD, 10 patients (1.4%) had a history of malignancy. Theprevalence of malignancy after the diagnosis of IBD was 13 (1.9%). There was a relationship between malignancy and older age, higherBMI, and female sex in survival analysis (p &lt; 0.05). There was no correlation with disease type and malignancy (p = 0.820). When thepatients who developed malignancy in IBD were compared in terms of the immunomodulators and biological agents used by the patients who did not develop malignancy, there was no statistical difference between the two groups (p &gt; 0.05).\nConclusion\u02d0 Older age, higher BMI, and female sex were found to be at risk for the development of malignancy in IBD, although norelationship was found with the use of immunomodulators, biological agents, or disease type.<\/jats:p>","DOI":"10.55730\/1300-0144.6036","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:31:06Z","timestamp":1756373466000},"page":"846-854","source":"Crossref","is-referenced-by-count":0,"title":["What are the predictors of malignancy in inflammatory bowel disease?"],"prefix":"10.55730","volume":"55","author":[{"given":"Z\u00dcLAL","family":"\u0130STEM\u0130HAN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u0130LGER","family":"\u00c7AVU\u015e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AL\u0130 EMRE","family":"BARDAK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AY\u015eE MERVE","family":"KIRKO\u011eLU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CANSU","family":"KIZILTA\u015e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00dcVEYDA","family":"S\u0130LAY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130BRAH\u0130M VOLKAN","family":"\u015eENKAL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z\u0130YA","family":"\u0130MANOV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KENAN","family":"NUR\u0130YEV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AYNURE","family":"R\u00dcSTEMZADE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SEZEN","family":"GEN\u00c7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u0130NE","family":"G\u00dcLL\u00dcO\u011eLU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ASLI","family":"\u00c7\u0130FC\u0130BA\u015eI \u00d6RMEC\u0130","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KAD\u0130R","family":"DEM\u0130R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FAT\u0130H","family":"BE\u015eI\u015eIK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SABAHATT\u0130N","family":"KAYMAKO\u011eLU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u0130L\u0130Z","family":"AKY\u00dcZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"34691","published-online":{"date-parts":[[2025,8,15]]},"container-title":["Turkish Journal of Medical Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:46:34Z","timestamp":1792680394000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.tubitak.gov.tr\/medical\/vol55\/iss4\/5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,15]]}},"URL":"https:\/\/doi.org\/10.55730\/1300-0144.6036","relation":{},"ISSN":["1300-0144"],"issn-type":[{"value":"1300-0144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]}}}